Surgical treatment
Uitgangsvraag
What is the added value of surgical treatment, compared to medical treatment only, for necrotizing otitis externa?
Aanbeveling
Treat patients with necrotizing otitis externa medically. There is no role for surgery as the primary treatment for patients with necrotizing otitis externa.
In the following scenarios a surgical approach can be chosen, apart from medical treatment:
- In case of failing treatment. A surgical approach for diagnostic purposes can be undertaken to improve the chance of a positive culture, or to exclude a different diagnosis. Ablative surgery as salvage treatment is not advised.
- No advise is given on the role for surgery in case of facial nerve palsy, due to the limited evidence.
Take into account that most patients with necrotizing otitis externa are frail. The risk of general anesthesia should also be considered and weighed in the (shared) decision making.
Overwegingen
Balance between desired and undesired effects
The systematic literature search yielded conflicting results in the few selected articles. Only one RCT was identified, which favored surgery for treatment response in patients with refractory necrotizing otitis externa who were unsuccessfully treated with antibiotics for 6 weeks. However, the methodological and statistical approaches were questionable (Singh, 2018). An observational study on the primary treatment of necrotizing otitis externa found no clinically relevant improvement in remission rates favoring surgical treatment over antibiotics alone (RR 1.15, 95% CI: 0.84 to 1.55) (Lambor, 2013).
Current literature cannot provide a clear answer regarding the role of surgery in necrotizing otitis externa. This is partly due to the rarity of the condition and partly because the cornerstone of treatment is medical. Recent trends also show a sharp decline in the use of extensive surgical therapy for the disease (which included mastoidectomy, facial nerve decompression, and/or middle ear exploration), with 13.3% of patients undergoing extensive surgery before 2009 compared to 3.7% after 2009 (Byun, 2020).
A variety of surgical options are described in the literature, ranging from nettoyage of the ear canal to lateral temporal bone resection. Based on the literature search, it is evident that no clear surgical indication exists. However, specific procedures could be considered for different indications. This list is explicitly not a hierarchical ste-by-step enumeration of treatment options; it is a list of treatment options that is opted for in literature in specific conditions.
- Nettoyage of the ear canal: This can be performed in combination with obtaining culture material or tissue biopsy for diagnostic purposes. Cleaning the ear canal of debris might not be considered a surgical intervention, but it is mentioned because it is reported in literature as (part of) a treatment.
- Other studies describe more extensive surgical interventions of the ear canal, including sequestrectomy and smoothing of bony irregularities / canalplasty. In our opinion, it is important not to confuse NOE with osteitis of the temporal bone for this indication. Osteitis due to a localized infection and/or inflammation can be a major cause of sequestra and epithelial defects in the ear canal, leading to granulation tissue and loss of the canal's migratory capacity. Moreover, prior radiotherapy of the parotid gland or nasopharynx can cause avascular necrosis or osteoradionecrosis of the temporal bone, leading to tissue defects as mentioned earlier, which can mimic NOE. Again, this should not be confused with NOE, especially because the nature of this problem is not primarily infectious.
- Mastoidectomy: The guideline panel believes that the main incentive for this procedure would be diagnostic, as local treatment of the ear canal might not reveal pathogens. Local epithelialization in the ear canal may be restored due to local treatment, whereas the infectious process can progress in deeper tissues. Mastoidectomy solely to reduce infectious load has been described but is considered obsolete.
- (Sub)total petrosectomy/lateral temporal bone resection: The most invasive type of surgery consists of (sub)total petrosectomy or lateral temporal bone resection. No evidence supports the indication for these procedures. These types of surgery could be considered as salvage surgery if all other treatments fail, potentially aiding in reducing disease burden. However, morbidity and mortality rates are high, making these procedures generally discouraged (Peleg, 2007; Omran, 2012).
- Facial nerve decompression: Facial nerve decompression in cases of facial nerve palsy is described as an indication for surgical intervention, with one study reporting its positive effects (Freeman, 2023). Facial nerve decompression is automatically performed in combination with mastoidectomy due to the surgical approach.
The extent of surgical intervention, if any, depends on multiple factors. Moreover, a combination of procedures can be chosen if indicated. The most obvious surgical indication is the search for a causative pathogen, especially in cases of failed initial medical treatment. Imaging can guide the determination of the anatomical area to approach for tissue sampling. The ear canal, mastoid, and skull base can be areas of interest, and occasionally the nasopharynx, if affected, is easily accessible.
Given the sparse literature available, it is difficult to provide clear recommendations. If no pathogen is identified, antibiotic treatment cannot be optimized, surgical intervention should be considered. The type of surgery will be determined on an individual basis and depends on multiple factors. Imaging reveals which areas are affected, guiding the choice of surgery. The clinical state of the patient, as well as cranial nerve involvement, is weighed in the decision to perform surgery. If there is a suspicion of malignancy tissue samples need to be obtained, and more invasive surgery might be necessary to collect relevant tissue samples. Unequivocally, antibiotic treatment will remain the primary treatment modality in case of NOE. Studies to determine the benefit of surgical interventions will continue to be challenging, as necrotizing otitis externa is rare and indications are unclear. However, a large multicenter study with clear indications might provide more insight into the role of surgery in the treatment of necrotizing otitis externa.
Quality of the evidence
The overall quality of evidence is very low. This means that the estimated effect of the critical outcomes that were found are very uncertain. There was a downgrade due to the following:
- Risk of Bias: methodological limitations.
- Inconsistency: inconsistency of the results.
- Indirectness: indirectness of the evidence, due to differences in the use of surrogate outcomes.
- Imprecision: inaccuracy, due to a very small number of events in a small sample size.
Moreover, the inconsistent terminology used in surgical approaches and the doubtful use of correct diagnoses might give a distorted image of literature, with a high risk of publication bias.
Values and preferences of patients (and possibly their caregivers)
Since studies describing surgery for necrotizing otitis externa are rare, it can be difficult to decide when to opt for surgery. Moreover, available reports are unclear and inconsistent regarding the type and extent of surgery. Patients should be informed about the goal of the procedure and the associated risks. The uncertainty of the outcome should also be addressed. The alternative to surgical intervention depends on the indication for the procedure. If the causative pathogen is unknown, surgery to obtain tissue samples is a reasonable indication. In cases of cranial nerve palsy, the indication and outcome are more uncertain, and both physicians and patients should be aware of this. If (optimal) conservative treatment does not result in clinical improvement, similar considerations must be made, and specialized (tertiary) centers should be consulted regarding further treatment.
Costs (resources)
Since surgery for NOE is rare, costs for this kind of treatment are negligible considering total treatment costs. However, no studies have been performed to show cost-effectiveness of the treatment, let alone for the surgery done in a small percentage of cases.
Equity ((health) equity/equitable)
The guideline panel expects no problems with health equity with regard to medical treatment of necrotizing otitis externa.
Acceptability
The guideline panel expects no problems with ethical acceptability or sustainability with regard to medical treatment of necrotizing otitis externa.
Feasibility
Regardless of the eventual recommendation, surgical intervention is feasible. The intervention is a treatment option for some clinicians. Even though the surgical procedure is feasible, the indication is complex, if existent, as mentioned before. Given this complexity the advice is to consult a specialist in NOE when surgery is considered in patients that do not seem to respond to conservative treatment. No specialized equipment is needed for surgical procedures.
Rationale of the recommendation: weighing arguments for and against the interventions
The literature on outcome or effect of surgical intervention as a standard treatment is of insufficient certainty and different studies all use different outcome measures. Therefore, the recommendations are expert opinions.
The available literature for surgical treatment in NOE suggests that surgery has a very limited role. The main indication for surgical exploration is in case of failing conservative treatment in case of an unknown causative pathogen.
There is insufficient available evidence on the effect of facial nerve decompression in case of facial nerve palsy in NOE.
Final judgment:
Weak recommendation against surgical intervention in patients with necrotizing otitis externa.
Onderbouwing
Achtergrond
It is generally accepted that the treatment of necrotizing otitis externa (NOE) involves long-term administration of antibiotics (or antimycotics in the case of fungal infections). In specific scenarios, surgical treatment may be considered:
- If no pathogen can be identified, surgery may be performed to obtain deep tissue samples. This is considered a diagnostic procedure rather than a curative treatment.
- If there is no or insufficient response to medical treatment; this is also referred to as salvage surgery.
- Surgery aimed at curing or preventing (further) damage to vital structures, such as the facial nerve or the inner ear.
Surgery in the infected area can be complex and carries risks, particularly in frail patients, which NOE patients often are.
Conclusies / Summary of Findings
PICO (1.1)
Population: Patients with proven necrotizing otitis externa
Intervention: Surgical treatment
Comparison: Medical treatment
Outcome Timeframe |
Study results and measurements |
Absolute effect estimates |
Certainty of the Evidence (Quality of evidence) |
Summary |
|
Medical treatment |
Surgical treatment |
||||
|
|||||
Survival
|
1 study reported no mortality |
- |
Very low By very serious imprecision2 |
The evidence is very uncertain about the effect of surgical management to improve survival in patients with skull base osteomyelitis.
(Freeman 2023) |
|
Remission
|
The risk ratio (RR) is 1.15 (95% CI: 0.84 to 1.55), based on 27 participant from one study. |
- |
Very low By very serious imprecision3 |
The evidence is very uncertain about the effect of surgical management to improve disease control in patients with skull base osteomyelitis.
(Lambor, 2013) |
|
Quality of life
|
-
|
- |
- |
No evidence was found about the effect of surgical management to improve the quality of life in patients with skull base osteomyelitis. |
1. Imprecision: very serious. Low population (<100)
2. Imprecision: very serious. Low population (<100)
3. Imprecision: very serious. Low population (<100)
Samenvatting literatuur
Description of studies
A total of 3 studies were included in the literature analysis. Key study characteristics and results are summarized in Table 1. The risk of bias assessment is summarized in the risk of bias tables (under the tab ‘Evidence tables’). One RCT (Singh, 2018) and two observational studies (Omran, 2012; Freeman, 2023) were included. For details, See also Table 1 below.
Table 1. Characteristics of included studies
*For further details, see risk of bias table in the appendix
Results
Survival (critical)
Freeman (2023) reported no deaths in both surgical and medical groups.
Remission (critical)
One study reported remission as an outcome measure (Singh, 2018). However, the authors did not report remission as a dichotomous result. Instead, to compare the treatment responses, the number of resolutions per criterion per group was assessed:
- Complete resolution of edema and granulation.
- Resolution of pain (nocturnal pain).
- Hearing loss resolution.
- No disease on post treatment gallium scan.
- Resolution of ear discharge.
- TM joint pain resolution.
Group A was the antibiotic group, and group B was the surgical group. To determine the preferred treatment for the overall best resolution of aforementioned criteria, a Mann–Whitney U test was applied, which found surgical treatment to be more effective. However, the exact methods are not specifically mentioned and are, therefore, not reproducible.
The number of patients with resolved disease on the post-treatment gallium scan were 6 out of 10 in group B versus 2 out of 10 in group A. The risk ratio (RR) was 3.0 (95% CI: 0.79 to 11.4), favoring the surgery group.
Lambor (2013) found a remission rate of 11 out of 12 in the surgery group and 12 out of 15 in the control group (Risk Ratio 1.12, 95% CI 0.85–1.55).
Quality of life (important)
None of the included studies reported quality of life as an outcome measure.
Zoeken en selecteren
A systematic review of the literature was conducted to address the following question:
What are the benefits and disadvantages of surgical treatment for necrotizing otitis externa compared to medical treatment?
Patients | Patients with proven necrotizing otitis externa |
Intervention |
Surgical treatment (with or without medical treatment) |
Control | Medical treatment |
Outcomes | (Disease specific) survival, remission, quality of life |
Other selection criteria | Study design: systematic reviews and randomized controlled trials |
Relevant outcome measures
The guideline panel considered remission, (disease-free) survival and disease control as critical outcome measures for decision-making; and quality of life as an important outcome measure for decision making.
The guideline panel defined the outcome measures as follows:
- Survival:
- Overall survival: Time to death from any cause.
- Disease free survival: Time to death, caused by the effects of necrotizing otitis externa/skull base osteomyelitis.
- Remission: Rate of curation of disease, defined after prolonged disappearance of the signs and symptoms of a disease.
- Health-related Quality of Life (HR-QoL): Preferably measured with EQ-5D-5L
The guideline panel defined the following as a minimal clinically (patient) important difference.
The guideline panel defined the following differences as a minimal clinically (patient) important difference.
- Remission: 25% difference in relative risk (GRADE standard limits)*
- Survival: 25% difference in relative risk (GRADE standard limits)*
- Quality of life: 25% difference in relative risk or 0.5 standard deviations difference (GRADE standard limits)*
* Default thresholds proposed by the international GRADE working group were used: a 25% difference in relative risk (RR) for dichotomous outcomes (RR <0.80 or RR >1.25), or 0.5 standard deviations (SD) for continuous outcomes
Search and select (Methods)
The databases Medline (via OVID) and Embase (via Embase.com) were searched using relevant search terms from 2000 until February 6th, 2023. The detailed search strategy is provided under the tab ‘Literature Search Strategy’. The systematic literature search yielded 456 unique hits. Studies were selected based on the following criteria: systematic reviews, RCTs, observational studies, and other non-comparative research on the value of surgical treatment for necrotizing otitis externa. Forty-six studies were initially selected based on title and abstract screening. After full-text review, 43 studies were excluded (see the table with reasons for exclusion under the tab ‘Evidence Tables’), and 3 studies were included.
Results
Three studies, consisting of 1 RCT and 2 observational studies, were included in the literature analysis. Key study characteristics and results are summarized in the evidence tables. The risk of bias assessment is summarized in the risk of bias tables.
Referenties
- Byun YJ, Patel J, Nguyen SA, Lambert PR. Necrotizing Otitis Externa: A Systematic Review and Analysis of Changing Trends. Otol Neurotol. 2020 Sep;41(8):1004-1011. doi: 10.1097/MAO.0000000000002723. PMID: 32569149.
- Freeman MH, Perkins EL, Tawfik KO, O'Malley MR, Labadie RF, Haynes DS, Bennett ML. Facial Paralysis in Skull Base Osteomyelitis - Comparison of Surgical and Nonsurgical Management. Laryngoscope. 2023 Jan;133(1):179-183. doi: 10.1002/lary.30161. Epub 2022 May 12. PMID: 35546515.
- Lambor DV, Das CP, Goel HC, Tiwari M, Lambor SD, Fegade MV. Necrotising otitis externa: clinical profile and management protocol. J Laryngol Otol. 2013 Nov;127(11):1071-7. doi: 10.1017/S0022215113002259. Epub 2013 Oct 29. PMID: 24169084.
- Omran AA, El Garem HF, Al Alem RK. Recurrent malignant otitis externa: management and outcome. Eur Arch Otorhinolaryngol. 2012 Mar;269(3):807-11. doi: 10.1007/s00405-011-1736-2. Epub 2011 Aug 11. PMID: 21833561.
- Peleg U, Perez R, Raveh D, Berelowitz D, Cohen D. Stratification for malignant external otitis. Otolaryngol Head Neck Surg. 2007 Aug;137(2):301-5. doi: 10.1016/j.otohns.2007.02.029. PMID: 17666260.
- Singh J, Bhardwaj B. The Role of Surgical Debridement in Cases of Refractory Malignant Otitis Externa. Indian J Otolaryngol Head Neck Surg. 2018 Dec;70(4):549-554. doi: 10.1007/s12070-018-1426-0. Epub 2018 Jun 18. PMID: 30464914; PMCID: PMC6224839.
Evidence tabellen
Risk of Bias tables
Risk of bias table for intervention studies (observational: non-randomized clinical trials, cohort and case-control studies
Study reference
(first author, year of publication) |
Bias due to a non-representative or ill-defined sample of patients?1
(unlikely/likely/unclear) |
Bias due to insufficiently long, or incomplete follow-up, or differences in follow-up between treatment groups?2
(unlikely/likely/unclear) |
Bias due to ill-defined or inadequately measured outcome ?3
(unlikely/likely/unclear) |
Bias due to inadequate adjustment for all important prognostic factors?4
(unlikely/likely/unclear) |
Lambor, 2013 |
Unlikely |
Unlikely |
likely |
Unclear |
Freeman, 2023 |
likely |
unlikely |
Likely |
Unclear |
Risk of bias table for intervention studies (randomized controlled trials; based on Cochrane risk of bias tool and suggestions by the CLARITY Group at McMaster University)
Study reference
(first author, publication year) |
Was the allocation sequence adequately generated?
|
Was the allocation adequately concealed?
|
Blinding:
|
Was loss to follow-up (missing outcome data) infrequent? |
Are reports of the study free of selective outcome reporting? |
Was the study apparently free of other problems that could put it at a risk of bias?
|
Overall risk of bias If applicable/necessary, per outcome measure
|
Singh, 2018 |
Definitely yes;
Reason: Central randomization with computer generated random numbers |
Probably no
Reason: concealment of allocation was not reported in the article |
Definitely no
Reason: Open-label trial (patients and health care providers not blinded), outcome assessors blinded (blinding of data collectors and analysts not reported) |
Definitely yes.
Reason: no patients were lost to follow up. |
definitely no;
Reason: only some symptoms reported, on which was decided that one therapy was better than the other. |
Definitely yes;
Reason: No other problems noted |
HIGH (Disease control) |
Table of excluded studies
Reference |
Reason for exclusion |
Das S, Iyadurai R, Gunasekaran K, Karuppusamy R, Mathew Z, Rajadurai E, John AO, Mani S, George T. Clinical characteristics and complications of skull base osteomyelitis: A 12-year study in a teaching hospital in South India. J Family Med Prim Care. 2019 Mar;8(3):834-839. doi: 10.4103/jfmpc.jfmpc_62_19. PMID: 31041210; PMCID: PMC6482749. |
Wrong population (also including non otogenic) |
Chawdhary G, Pankhania M, Douglas S, Bottrill I. Current management of necrotising otitis externa in the UK: survey of 221 UK otolaryngologists. Acta Otolaryngol. 2017 Aug;137(8):818-822. doi: 10.1080/00016489.2017.1295468. Epub 2017 Mar 16. PMID: 28301961. |
No comparison made |
Chawdhary G, Pankhania M, Douglas S, Bottrill I. Current management of necrotising otitis externa in the UK: survey of 221 UK otolaryngologists. Acta Otolaryngol. 2017 Aug;137(8):818-822. doi: 10.1080/00016489.2017.1295468. Epub 2017 Mar 16. PMID: 28301961. |
Wrong study design |
Peled C, Parra A, El-Saied S, Kraus M, Kaplan DM. Surgery for necrotizing otitis externa-indications and surgical findings. Eur Arch Otorhinolaryngol. 2020 May;277(5):1327-1334. doi: 10.1007/s00405-020-05842-x. Epub 2020 Feb 12. PMID: 32052142. |
No comparison made |
Verantwoording
Beoordelingsdatum en geldigheid
Laatst beoordeeld : 25-09-2025
Algemene gegevens
For more details on the guideline methodology used, we refer you to the Werkwijze. Relevant information for the development of this guideline is presented below.
The revision of this guideline module was supported by the Knowledge Institute of the Federation of Medical Specialists (www.demedischspecialist.nl/kennisinstituut) and was funded by the Quality Funds for Medical Specialists (SKMS).
Samenstelling werkgroep
For the development of the guideline, a multidisciplinary guideline development group was established in 2022, consisting of representatives from all relevant specialties (see Composition of the working group) involved in the care of patients with necrotizing otitis externa.
Werkgroep
- Dr. J.J. (Jérôme) Waterval (chairman), Nederlandse Vereniging voor Keel-Neus-Oorheelkunde en Heelkunde van het Hoofd-Halsgebied, otorhinolaryngologist, Maastricht University Medical Center, Maastricht; Academic Alliance Skull Base Pathology Maaastricht University Medical Center – Radboud University Medical Center
- Dr. M.J. (Mark) van Tilburg, Nederlandse Vereniging voor Keel-Neus-Oorheelkunde en Heelkunde van het Hoofd-Halsgebied, otorhinolaryngologist, Elistabeth-TweeSteden Ziekenhuis, Tilburg
- Drs. S.A.H. (Sjoert) Pegge, Nederlandse Vereniging voor Radiologie, radiologist, Radboud University Medical Center, Nijmegen; Academic Alliance Skull Base Pathology Maaastricht University Medical Center – Radboud University Medical Center
- Prof. Dr. A.W.J.M. (Andor) Glaudemans, Nederlandse Vereniging voor Nucleaire Geneeskunde, nuclear physicist UMCG, Groningen
- Dr. M. (Moniek) Heusinkveld, Nederlandse Vereniging voor Medische Microbiologie, medical microbiologist, Gelderse Vallei Hospital, Ede
- Dr. E.J.G. (Edgar) Peters, Nederlandse Internisten Vereniging, infectious disease specialist, Amsterdam University Medical Center (tot oktober 2022)
- Dr. J.J. (Jonne) Sikkens, Nederlandse Internisten Vereniging, infectious disease specialist, Amsterdam University Medical Center (vanaf october 2022)
- Dr. I.R. (Raluca) Mihailescu, Nederlandse Internisten Vereniging, infectious disease specialist, Onze Lieve Vrouwe Gasthuis, Amsterdam (vanaf juli 2024)
- Dr. S.H. (Selwyn) Lowe, Nederlandse Internisten Vereniging, infectious disease specialist, Maastricht University Medical Center, Maastricht (vanaf juli 2024)
Klankbordgroep
- Dr. N.G.L. (Nynke) Jager, NVZA, hospital pharmacist Radboud University Medical Center, Nijmegen
- Drs. F.S. (Fleur) Sinkeler, NVZA, hospital pharmacist Radboudumc Nijmegen
Ondersteuning
- Drs. J.M.H. (Jasper) Janssen, NVKNO, otorhinolaryngologist in training, Maastricht University Medical Center, Maastricht
- Dr. A. (Anja) van der Hout, advisor Knowledge Institute of the Dutch Association of Medical Specialists
Belangenverklaringen
An overview of the conflicts of interests of the guideline development group members and the assessment of how potential conflicts of interest were addressed can be found in the table below. The signed declarations of interest are available upon request from the Secretariat of the Knowledge Institute of the Dutch Federation of Medical Specialists at secretariaat@kennisinstituut.nl.
Werkgroeplid |
Functie |
Nevenfuncties |
Gemelde belangen |
Ondernomen actie |
Waterval (voorzitter) |
KNO-arts MUMC |
Accreditatiecommissie Stichting Audiciensregister |
Geen |
Geen |
Glaudemans |
Nucleair geneeskundige UMCG
|
Voorzitter NVNG (onbetaald) |
We hebben als ziekenhuis en afdeling een samenwerking met Siemens (UMCG-Siemens PUSH collaboration/Partnership of UMCG-Siemens for building the future of Health). Hieruit vloeit uit voort dat de nieuwste camera’s bij ons komen (bv UMCG neemt nieuwe Whole-Body PET/CT-scanner in gebruik) en dat er gezamenlijk onderzoek gedaan wordt. Hierbij heb ik een aantal promovendi die door Siemens betaald worden (niet op het gebied van osteomyelitis schedelbasis) |
Geen restricties. Extern gefinancierd onderzoek valt buiten bestek richtlijn
|
Heusinkveld |
Arts-microbioloog in ziekenhuis Gelders Vallei |
Richtlijn otitis externa
Bestuur SKML sectie infectieserologie (onbetaald) |
Geen |
Geen |
Peters (tot oktober 2022) |
Internist-infectioloog-acute geneeskundige, Amsterdam UMC |
richtlijnontwikkeling: Covid-19 FMS, diabetische voet NIV, diabetische voet IWGDF, alle onbetaald
|
afdeling krijgt geld van Roche voor biomarker onderzoek bij diabetische voet osteomyelitis Diabetische voet onderzoek (extern gefinancierd)
|
Geen restricties. Extern gefinancierd onderzoek valt buiten bestek richtlijn
|
Pegge |
Radioloog (Neuro/Hoofdhals) Radboud UMC Nijmegen |
Geen |
Geen |
Geen |
Van Tilburg |
KNO-arts ETZ
|
Geen |
Geen |
Geen |
Sikkens |
Internist acute geneeskunde & infectioloog, Amsterdam UMC |
post-doc onderzoeker Amsterdam UMC, onbetaald
|
Ja, via ZonMw (onderzoek naar COVID bij een medewerkerscohort, onderwerp infectiepreventie en vaccin-immunologie)
|
Geen restricties. Extern gefinancierd onderzoek valt buiten bestek richtlijn
|
Lowe
|
Internist-infectioloog. Afdeling Medische Microbiologie, Infectieziekten en Infectiepreventie (MMI), Maastricht UMC+
|
Geen |
Geen |
Geen |
Mihailescu
|
Internist-infectioloog OLVG Amsterdam |
Geen |
Geen |
Geen |
Jasper Janssen
|
KNO-arts in opleiding bij het MUMC+ (0,8 FTE), promovendus (0,2 FTE). |
Geen |
Geen |
Geen |
Sinkeler
|
Ziekenhuisapotheker AmsterdamUMC
|
Geen |
Geen |
Geen |
Jager |
Ziekenhuisapotheker
|
Geen |
Geen |
Geen |
Inbreng patiëntenperspectief
Attention was paid to the patient perspective by inviting Stichting Hoormij and Patiëntenfederatie Nederland for the invitational conference, and close contact with Stichting Hoormij during the development of the guideline. The report of this [see related products] was discussed in the guideline development group. The input obtained was taken into account when formulating the key questions, selecting the outcome measures, and drafting the considerations. The draft guideline was also submitted for comments to Stichting Hoormij and Patiëntenfederatie Nederland, and any comments received were reviewed and processed.
Kwalitatieve raming van mogelijke financiële gevolgen in het kader van de Wkkgz
Bij de richtlijnmodule voerde de werkgroep conform de Wet kwaliteit, klachten en geschillen zorg (Wkkgz) een kwalitatieve raming uit om te beoordelen of de aanbevelingen mogelijk leiden tot substantiële financiële gevolgen. Bij het uitvoeren van deze beoordeling is de richtlijnmodule op verschillende domeinen getoetst (zie het stroomschema bij Werkwijze).
Module |
Uitkomst raming |
Toelichting |
Surgical treatment |
geen financiële gevolgen |
Uit de toetsing volgt dat de aanbeveling(en) niet breed toepasbaar zijn (<5.000 patiënten) en daarom naar verwachting geen substantiële financiële gevolgen zal hebben voor de collectieve uitgaven. |
Zoekverantwoording
Algemene informatie
Cluster/richtlijn: Osteomyelitis schedelbasis – maligne otitis externa |
|
Uitgangsvraag/modules: Wat is de waarde van chirurgische behandeling bij maligne otitis externa, ten opzichte van alleen medicamenteuze behandeling? |
|
Database(s): Ovid/Medline, Embase.com |
Datum: 6 februari 2023 |
Periode: 2000* - heden |
Talen: Engels, Nederlands |
Literatuurspecialist: Miriam van der Maten |
|
BMI-zoekblokken: voor verschillende opdrachten wordt (deels) gebruik gemaakt van de zoekblokken van BMI-Online https://blocks.bmi-online.nl/ Bij gebruikmaking van een volledig zoekblok zal naar de betreffende link op de website worden verwezen. |
|
Toelichting: Voor deze vraag is gezocht op de elementen:
→ De opgegeven sleutelartikelen worden gevonden met de zoekopdracht → Er is gezocht met major/focus Emtree/MeSH en in titel/keyword i.p.v. titel/abstract/keyword om ruis eruit te filteren.
*Er is gezocht vanaf het jaar 2000. Terugkomend op de opmerking van het zoekformulier, verder terugzoeken zal minimaal 250 hits extra betekenen. |
|
Te gebruiken voor richtlijnen tekst: Nederlands In de databases Embase.com en Ovid/Medline is op 6 februari 2023 systematisch gezocht naar systematische reviews, RCT, observationele studies, niet-vergelijkend onderzoek over de waarde van chirurgische behandeling bij maligne otitis externa. De literatuurzoekactie leverde 456 unieke treffers op.
Engels On the 6th of February 2023, we performed a systematic search in the databases Embase.com and Ovid/Medline to find systematic reviews, RCT, observational studies, and other non-comparative research about the value of surgical treatment for malignant external otitis. The search resulted in 456 unique hits. |
Zoekopbrengst
|
EMBASE |
OVID/MEDLINE |
Ontdubbeld |
SRs |
14 |
14 |
21 |
Overige designs |
234 |
325 |
435 |
Totaal |
248 |
339 |
456 |
Zoekstrategie
Embase.com
No. |
Query |
Results |
#10 |
#8 OR #9 |
248 |
#9 |
#6 NOT #8 = overige designs |
234 |
#8 |
#6 AND #7 = SR |
14 |
#7 |
'meta analysis'/exp OR 'meta analysis (topic)'/exp OR metaanaly*:ti,ab OR 'meta analy*':ti,ab OR metanaly*:ti,ab OR 'systematic review'/de OR 'cochrane database of systematic reviews'/jt OR prisma:ti,ab OR prospero:ti,ab OR (((systemati* OR scoping OR umbrella OR 'structured literature') NEAR/3 (review* OR overview*)):ti,ab) OR ((systemic* NEAR/1 review*):ti,ab) OR (((systemati* OR literature OR database* OR 'data base*') NEAR/10 search*):ti,ab) OR (((structured OR comprehensive* OR systemic*) NEAR/3 search*):ti,ab) OR (((literature NEAR/3 review*):ti,ab) AND (search*:ti,ab OR database*:ti,ab OR 'data base*':ti,ab)) OR (('data extraction':ti,ab OR 'data source*':ti,ab) AND 'study selection':ti,ab) OR ('search strategy':ti,ab AND 'selection criteria':ti,ab) OR ('data source*':ti,ab AND 'data synthesis':ti,ab) OR medline:ab OR pubmed:ab OR embase:ab OR cochrane:ab OR (((critical OR rapid) NEAR/2 (review* OR overview* OR synthes*)):ti) OR ((((critical* OR rapid*) NEAR/3 (review* OR overview* OR synthes*)):ab) AND (search*:ab OR database*:ab OR 'data base*':ab)) OR metasynthes*:ti,ab OR 'meta synthes*':ti,ab |
898726 |
#6 |
#4 AND #5 AND [2000-2023]/py NOT ('conference abstract'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it) NOT (('animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp) |
248 |
#5 |
'surgery'/exp/mj OR 'surgical patient'/exp/mj OR 'surgical risk'/exp/mj OR 'perioperative period'/exp/mj OR surgic*:ti,kw OR surger*:ti,kw OR operation*:ti,kw OR operative:ti,kw OR presurg*:ti,kw OR preoperati*:ti,kw OR 'pre-surg*':ti,kw OR 'pre-operati*':ti,kw OR perisurg*:ti,kw OR perioperati*:ti,kw OR 'peri-surg*':ti,kw OR 'peri-operati*':ti,kw OR postsurg*:ti,kw OR postoperati*:ti,kw OR 'post-surg*':ti,kw OR 'post-operati*':ti,kw OR 'debridement'/exp OR 'debridement':ti,ab,kw OR resect*:ti,ab,kw OR mastoidectom*:ti,ab,kw |
3894874 |
#4 |
'malignant otitis externa'/exp/mj OR (((maligna* OR necroti* OR necrosis) NEAR/3 ('otitis externa' OR 'external otitis')):ti,kw) OR ('otitis externa'/mj AND (maligna*:ti,kw OR necroti*:ti,kw OR necrosis:ti,kw)) OR (('osteomyelitis'/exp/mj OR 'osteomyelitis':ti,kw) AND ('skull'/exp/mj OR 'skull disease'/exp/mj OR skull*:ti,ab,kw OR cranial:ti,ab,kw OR cranium:ti,ab,kw)) |
3086 |
Ovid/Medline
# |
Searches |
Results |
9 |
7 or 8 |
339 |
8 |
5 not 7= overige designs |
325 |
7 |
5 and 6 = SR |
14 |
6 |
meta-analysis/ or meta-analysis as topic/ or (metaanaly* or meta-analy* or metanaly*).ti,ab,kf. or systematic review/ or cochrane.jw. or (prisma or prospero).ti,ab,kf. or ((systemati* or scoping or umbrella or "structured literature") adj3 (review* or overview*)).ti,ab,kf. or (systemic* adj1 review*).ti,ab,kf. or ((systemati* or literature or database* or data-base*) adj10 search*).ti,ab,kf. or ((structured or comprehensive* or systemic*) adj3 search*).ti,ab,kf. or ((literature adj3 review*) and (search* or database* or data-base*)).ti,ab,kf. or (("data extraction" or "data source*") and "study selection").ti,ab,kf. or ("search strategy" and "selection criteria").ti,ab,kf. or ("data source*" and "data synthesis").ti,ab,kf. or (medline or pubmed or embase or cochrane).ab. or ((critical or rapid) adj2 (review* or overview* or synthes*)).ti. or (((critical* or rapid*) adj3 (review* or overview* or synthes*)) and (search* or database* or data-base*)).ab. or (metasynthes* or meta-synthes*).ti,ab,kf. |
650866 |
5 |
limit 4 to yr="2000 -Current" |
339 |
4 |
3 not (comment/ or editorial/ or letter/ or ((exp animals/ or exp models, animal/) not humans/)) |
580 |
3 |
1 and 2 |
606 |
2 |
exp *Surgical Procedures, Operative/ or exp *Specialties, Surgical/ or exp *Perioperative Period/ or surgic*.ti,kf. or surger*.ti,kf. or operation*.ti,kf. or operative.ti,kf. or presurg*.ti,kf. or preoperati*.ti,kf. or pre-surg*.ti,kf. or pre-operati*.ti,kf. or perisurg*.ti,kf. or perioperati*.ti,kf. or peri-surg*.ti,kf. or peri-operati*.ti,kf. or postsurg*.ti,kf. or postoperati*.ti,kf. or post-surg*.ti,kf. or post-operati*.ti,kf. or exp Debridement/ or 'debridement'.ti,ab,kf. or resect*.ti,ab,kf. or mastoidectom*.ti,ab,kf. |
3205775 |
1 |
((maligna* or necroti* or necrosis) adj3 ('otitis externa' or 'external otitis')).ti,kf. or (exp *Otitis Externa/ and (maligna* or necroti* or necrosis).ti,kf.) or ((exp *Osteomyelitis/ or 'osteomyelitis'.ti,kf.) and (exp Skull/ or skull*.ti,ab,kf. or cranial.ti,ab,kf. or cranium.ti,ab,kf.)) |
2625 |